The incidence and predictors of non-gastrointestinal (GI) adverse events (AEs) after colonoscopy are not well-understood. We studied the effects of antithrombotic agents, cardiopulmonary comorbidities, and age on risk of non-GI AEs after colonoscopy.
(CV), pulmonary, and neurovascular events have also been reported 2, 6, 7 and are typically not seen by gastroenterologists because of dispersed postprocedure care.
Older patients and patients with CV and sedation risk factors could be at increased risk of CV, pulmonary, and neurovascular events after colonoscopy. 3, [8] [9] [10] [11] Furthermore, in addition to the risk of cardiopulmonary comorbidities per se, antithrombotic management is of particular concern when considering the risk of non-GI events after colonoscopy. Specifically, the balance between bleeding risk if remaining on antithrombotics versus thromboembolic events if discontinuing therapy is a critical factor. 12, 13 However, the incidence of postprocedural non-GI AEs after colonoscopy in elevatedrisk patients, particularly patients with CV disease severe enough to require prescription antithrombotic management, has not been well-studied.
This retrospective analysis included 2 sequential aims. The first was to assess the incidence of non-GI AEs after colonoscopy in patients with cardiopulmonary comorbidities compared with patients without cardiopulmonary comorbidities. The second was to assess the incidence of non-GI AEs in elevated-risk patients with colonoscopy compared with a 1:1 matched group of elevated-risk patients without colonoscopy.
Methods

Data Source and Patient Cohort
Diagnosis, procedure, and prescription drug codes were used to assess patient comorbid risk and track in-hospital or emergency room (ER) non-GI AEs 30 days after colonoscopy in this retrospective cohort study. The data source was the IMS LifeLink Health Claims Database, which comprises fully adjudicated medical and pharmaceutical claims for >74 million unique patients from >80 United States commercial health plans (Supplementary Sections 1 and 8). No identifiable protected health information was extracted from the Health Insurance Portability and Accountability Act-compliant claims database, exempting this study from an institutional review board approval requirement.
Codes were identified and agreed on by consensus opinion of expert physician authors specializing in GI or CV disease. A complete list of codes used for patient comorbid conditions, prescriptions, colonoscopy procedures, and AEs are listed in the Supplementary Material.
All continuously enrolled patients from March 1, 2010 through March 31, 2012 were included. To ensure a complete longitudinal analysis, patients who died in that period (including the 30 days after colonoscopy) were not included. The 12-month index period was March 1, 2011 through February 29, 2012. The index event was defined as the first colonoscopy per patient in the index period. All colonoscopy was outpatient and included both screening and diagnostic purposes on the basis of the codes provided in Supplementary Table 1. For patients without colonoscopy, the index date was randomly assigned. A 12-month look-back period (March 1, 2010-February 28, 2011) provided medication and diagnosis history, and a 30-day look-forward period (March 1, 2012-March 31, 2012) identified events after the colonoscopy beginning on the day after the colonoscopy procedure.
Analysis Sets
Analysis #1 consisted of all patients undergoing outpatient colonoscopy and compared an averagerisk group with 2 different elevated-risk groups ( Figure 1A ). Elevated-risk included patients prescribed antithrombotics for preexisting CV conditions and/or patients with pulmonary risk factors. To be included in the antithrombotic group, a patient must have had both a prescription for an antiplatelet or anticoagulant medication filled and a diagnosis code associated with a CV condition in the 12 months before colonoscopy. The pulmonary risk group included patients diagnosed with obstructive sleep apnea (OSA) or chronic obstructive pulmonary disease (COPD). Although there are other sedation risk factors, these groups were chosen as the most common disease diagnoses, with published evidence suggesting increased risk in general surgical settings but less evidence after colonoscopy in high-risk groups. The average-risk group consisted of patients without these preconditions (although they could have had other risk factors not assessed in this analysis). Outcomes were also evaluated according to patient gender, age, and whether the colonoscopy included an intervention.
Analysis #2 consisted of the subset of elevated-risk patients with colonoscopy in Analysis #1 who could be 1:1 matched to a cohort of patients who did not have a colonoscopy ( Figure 1B) . Stepwise matching was conducted on the basis of age, gender, comorbidity, and antithrombotic prescriptions (Supplementary Section 6).
Analyses and Statistics
Outcomes were the occurrence of non-GI AEs 1-30 days after outpatient colonoscopy. Only events presenting in-hospital or at the ER were included. Only the first AE reported for each patient was tracked, minimizing the possibility of over-reporting because of "ripple effects" (for example, a primary GI AE causing a secondary CV AE). All patient inpatient and ER visits were captured, even if the patient moved to a different location or specialty, as long as the patient remained in one of the included health plans.
Non-GI AEs captured included (1) cardiac events (myocardial infarction, valvular heart disease, atherosclerosis, heart failure, cardiac arrest, acute pulmonary heart disease, cardiac dysrhythmias, acute stent/valve thrombosis, percutaneous coronary intervention); (2) pulmonary events (sedation AEs, including oversedation, respiratory arrest, aspiration pneumonia, anoxic brain injury, hypercarbia, hypoxia, pulmonary edema, apnea, and alterations in consciousness); and (3) neurovascular events (cerebrovascular disease, including intracranial and extracranial occlusion or stenosis and postoperative stroke, peripheral vascular disease, GI and kidney ischemia or infarction, and retinal artery occlusion).
Analyses were performed by using SAS Version 9.4 (SAS Inc, Cary, NC). Rates were calculated for categorical data. Univariate and multivariate logistic regression methods were used to calculate odds ratios (ORs) and 95% confidence interval. The c 2 tests were used for all tests of association. Codes included in the univariate and multivariate analyses are shown in Supplementary Section 5.
Results
Analysis #1: Non-gastrointestinal Adverse Events in Average-risk Versus Elevated-risk Patients After Colonoscopy Among the 488,506 colonoscopy patients, 53.8% were male, and 61.4% were less than age 60. Table 1 shows event rates for non-GI AEs 1-30 days after colonoscopy in the elevated-risk groups. Most non-GI AEs (94%) occurred within 2 weeks after colonoscopy. In univariate analyses (Figure 2A ), non-GI AE rates after colonoscopy were higher in patients prescribed antithrombotics for CV disease and in those with pulmonary comorbidities compared with average-risk patients. Anticoagulant medications and combined prescriptions for both antiplatelets and anticoagulants conferred higher risk for AEs after colonoscopy. The risk of non-GI AEs was also significantly increased in patients with both antithrombotic prescriptions and pulmonary comorbidities, compared with average-risk patients (OR, 16.34 [15.08-17.71] ; not shown in Figure 2 ). The increased risk in patients with COPD and OSA was moderate, with the highest increased risk observed in patients with both of these conditions. Univariate analyses of age, gender, and colonoscopy with intervention are shown in Figure 2C . The risk of non-GI AEs after colonoscopy by age followed a non-linear trend, with relatively stable risk at ages <18 years old (0.6%), 18-34 years (0.6%), 35-49 years (0.7%), and 50-59 years (0.7%) and increasing sharply at 60-69 years (1.5%), 70-74 years (3.0%), and 75 years or older (5.3%). The increased risk in patients with COPD and OSA was moderate, with the highest increased risk observed in patients with both of these conditions. Male patients had a slight increase in risk compared with female patients. These results were confirmed in a multivariate analysis ( Figure 2B and D).
Colonoscopy with intervention conferred a slightly higher risk than colonoscopy without intervention. Among all 488,506 patients, post-colonoscopy non-GI AEs were higher after colonoscopy with bleeding control (4.7%), balloon dilation or stent placement (4.0%), or submucosal injection (3.9%), compared with polypectomy (1.4%), ablation (1.0%), or biopsy without intervention (1.3%). Colonoscopy coded as G0105 (highrisk screening) and G0121 (screening with barium enema) had lower non-GI AE rates (0.9% and 0.8%, respectively).
Additional unadjusted regression analyses crossing age and comorbidity ( Figure 3 ) showed that compared with average-risk patients younger than 50 years, delayed non-GI AE risk after colonoscopy was significantly increased in all elevated-risk patients 50 years or older and all average-risk patients 60 years or older. Anticoagulant prescription was associated with the greatest increased risk for all age groups. Figure 4A ), delayed non-GI AEs were more frequent in patients who had a colonoscopy in the past 30 days versus those who had not undergone a colonoscopy. This increase was driven by significantly increased rates of cardiac and neurovascular events. There was no statistically significant increase in pulmonary events. Among patients prescribed anticoagulants, the risk of non-GI AEs was significantly higher in patients with colonoscopy compared with matched patients without colonoscopy ( Figure 4B ). In contrast, the increased risk associated with colonoscopy was not statistically significant in patients prescribed antiplatelets alone.
In 1:1 matched patients with pulmonary comorbidities, delayed non-GI AE rates were significantly higher in patients with colonoscopy versus those who had not undergone colonoscopy ( Figure 4C ). The increased risk was statistically significant for cardiac events but not for pulmonary or neurovascular events. A statistically significant increase in non-GI AE risk was seen in patients with COPD but not in patients with OSA ( Figure 4D ).
Discussion
The objective of the study was to identify the incidence of non-GI AEs after colonoscopy in certain highrisk patient subgroups, with a primary focus on the impact of CV conditions requiring antithrombotic management, pulmonary comorbidities, and age.
Results showed that 18% of colonoscopy patients were prescribed antithrombotic medications or had pulmonary comorbid risk factors, and 12% of patients were 70 years or older. The presence of antithrombotic prescriptions, cardiopulmonary comorbidities, and higher age all increased the risk of non-GI AEs after colonoscopy. Although some of the captured events are unlikely to be directly related to colonoscopy complications, this broad scope allows the capture of all possible events after colonoscopy within the constraints of the claims database (for example, an ER visit for myocardial infarction coded as atherosclerosis). In addition, although it may be expected that patients with these risk factors are naturally at a higher risk of complications after colonoscopy (or any procedure), the 1:1 matched analysis demonstrates that complication rates were higher in elevated-risk patients with colonoscopy compared with matched elevated-risk patients without colonoscopy.
These results contrast with an analysis by Stock et al, 6 which examined non-GI AEs requiring hospitalization in 33,086 colonoscopy patients compared with matched patients without colonoscopy on the basis of a German health fund database. The study found no significant difference in the risk of non-GI AEs (including primarily myocardial infarction and stroke) between patients with colonoscopy and those without colonoscopy; however, Stock et al evaluated a heterogeneous health claims database that did not assess outcomes specifically in high-risk patient groups. Another published report found that AE rates were not significantly different between high-risk patients with colonoscopy and a matched cohort of high-risk patients without colonoscopy; however, prescription antithrombotics were not assessed. 14 The current results demonstrated that patients prescribed antithrombotics had a significant 10.8-fold increased risk of delayed non-GI AEs after colonoscopy compared with average-risk patients undergoing colonoscopy and a 2.3-fold increased risk compared with a 1:1 matched cohort not undergoing colonoscopy. Antithrombotic discontinuation before colonoscopy could explain the observed increase in post-colonoscopy CV events in this study. The management of antithrombotics represents a clinical dilemma before ordering colonoscopy, and the physician must carefully balance the risk for GI bleeding if remaining on antithrombotics with the risk for cardiopulmonary and neurologic AEs if antithrombotics are stopped temporarily. In addition, there is wide variation in practice patterns for antithrombotic discontinuation both before and after colonoscopy. National society guidelines have emphasized that clinical decision-making must weigh the overall risks and benefits, taking into account both CV and GI-related events, when considering colonoscopy in patients taking antithrombotics. 12, 13, 15 Patients with pulmonary comorbidities had only a moderate 1.3-fold higher risk of non-GI AEs after colonoscopy compared with a 1:1 matched group without colonoscopy, driven by increased risk in patients with COPD. Both COPD and OSA are risk factors after surgery in which even low doses of anesthetic may trigger cardiopulmonary AEs. 8, 10, 16 However, in the current study, the increase in non-GI events in patients with pulmonary risk was primarily seen in cardiac events, with no significant difference in pulmonary events in the 1:1 matched analysis. Further research is required to understand the impact of COPD on AEs after colonoscopy. Of note, the current analysis did not capture the type of anesthesia administered, which could certainly impact sedation risk. A recent commercial claims analysis examining moderate versus deep sedation with propofol during colonoscopy found that colonic perforation, anesthesia-associated complications, and cardiopulmonary outcomes were 13% higher in colonoscopies with anesthesia services (comprising 34% of all colonoscopies) compared with those without anesthesia services. This was largely due to increases in perforation, hemorrhage, and abdominal pain. 17 Older age is a known risk factor for postoperative AEs after colonoscopy. 3, 9, 18, 19 In a meta-analysis of 20 studies evaluating perforation, bleeding, CV and pulmonary events, and mortality after colonoscopy, the overall rate of AEs was significantly higher in patients 80 years or older compared with patients 65 years or older, driven largely by a higher incidence of cardiopulmonary events. 19 The current analysis showed that there is an increasing risk of delayed non-GI AEs after colonoscopy with increasing age. Importantly, the risk of non-GI AEs was higher in patients older than age 60 even with no comorbidities. Thus, although comorbidities, concomitant medications, and sedation risk may all contribute to the AE rates, the risk appears to increase with age even in healthy individuals.
There are limitations to the study. The LifeLink Database tracks prescription fulfillment only. Actual patient compliance, pre-procedure antithrombotic discontinuation or bridging, over-the-counter antiplatelet medications (including aspirin), and hospital pharmacy orders could not be tracked. Consistent with prior studies, 14 patients must have been enrolled for full 25-month study period to ensure a full longitudinal analysis. Patients who died in that period were not included, and the number of deaths is unknown; thus, AEs preceding death may have been underreported. The original indication for colonoscopy and the number of polyps diagnosed or treated were unknown. Although most events occurred in the first 2 weeks after colonoscopy, a more detailed breakdown of the timing is not available. Ascertainment of all outcomes, comorbidities, and other predictors was dependent on the definitions built around administrative codes; other unmeasured patient demographics, comorbidities, and risk factors could also impact AE rates after colonoscopy.
Despite the inherent limitations of any analysis based on a claims database, this approach also has a number of important strengths that cannot be duplicated in chart-based or prospective studies, most notably the ability to track patient events after procedure across specialties, geographies, and insurance plans. To our knowledge, this is the largest study to date that specifically examines non-GI AEs in elevated-risk patients, with a multidisciplinary evaluation of cardiac, pulmonary, and neurovascular extraction codes developed by both GI and CV experts, including assessment of antithrombotic medications. The analysis also includes a majority of patients younger than age 65, which have been underrepresented in prior Medicare-based analyses of post-colonoscopy complication rates. Second, the inclusive IMS database allowed the capture of all patient AEs resulting in ER visits or hospitalization in the 30 days after colonoscopy. Events were specifically time-associated with a colonoscopy, reducing reporting bias and maximizing the capture rate. Both of these factors may have limited colonoscopy-associated non-GI AEs reported in prior studies to date. In addition, by reporting events only presenting in-hospital or at the ER beginning on the day after the colonoscopy through 30 days (excluding codes occurring on the day of the colonoscopy), the analysis is focused on major postprocedural events after outpatient colonoscopy. Third, by capturing only the first event reported in each patient, the current analysis minimizes duplicate reporting, while allowing for granularity in assessing the specific risk of colonoscopy-related, non-GI AEs. Finally, the use of 1:1 matching that is based on an extensive comorbidity assessment allowed the identification of stratified risks and ensured that the observed differences could be attributed to the colonoscopy itself rather than comorbid risk factors.
Conclusions
Physicians performing colonoscopy typically focus on the prevention and reporting of procedurally related GI AEs such as bleeding and perforation. This is primarily because non-GI events after colonoscopy are not typically seen by gastroenterologists because of dispersed post-procedure care into other specialties. The current claims-based analysis provides a means to track serious post-colonoscopy events across specialties and suggests that certain subsets of high-risk patients have an increased and extended 30-day incidence of potentially serious cardiac and neurovascular AEs after colonoscopy compared with average-risk and 1:1 matched patients. Although the precise impact of antithrombotic discontinuation on post-colonoscopy CV events requires further research, this study highlights the importance of non-GI risk evaluation before colonoscopy.
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Section 1: Data Source
Data for this retrospective cohort study were obtained from the IMS LifeLink Health Claims Database, which comprises Health Insurance Portability and Accountability Act-compliant, fully adjudicated medical and pharmaceutical claims for more than 74 million unique patients from more than 80 commercial and managed care health plans across the United States. This database is the largest, most comprehensive database of integrated medical claims in the United States. Investigations that use this database have been widely published in peerreviewed journals (see Supplementary Section 8) .
The database includes both inpatient and outpatient diagnoses and procedures as well as both retail and mail order prescription records. Records are representative of the national, commercially insured population on a variety of demographic measures, including age, gender, and plan type. The data are longitudinal, with an average member enrollment time of 2 years. Only health plans submitting data for all members are included in the database, ensuring complete data capture and representative samples. Contributions are also subjected to a series of certification and data quality checks to ensure a standardized format and minimal error rates.
Codes were identified and agreed on by expert physician authors specializing in both GI and CV disease.
Inpatient and outpatient diagnoses were based on the International Classification of Diseases Ninth Revision Clinical Modification (ICD-9-CM). Procedures were identified on the basis of Current Procedural Terminology (CPT-4) and Centers for Medicare & Medicaid Services Healthcare Common Procedure Coding System codes from patients' medical claims. Prescription records were identified on the basis of National Drug Codes from pharmacy claims (including code and quantity dispensed). A complete list of codes used for patient comorbid conditions, prescriptions, colonoscopy procedures, and complications is below.
Section 2: Data Codes for Colonoscopy
Patients selected for inclusion in Analysis #1 were those receiving an outpatient colonoscopy during the selection period of March 1, 2011 through February 28, 2012. The index event was defined as the first colonoscopy per patient in the index window.
NOTE. Because of the nature of the database, the codes in Supplementary Table 1 indicate what was actually done rather than the a priori indication for the colonoscopy. For example, if a patient presents for a screening colonoscopy and a polyp is found and removed, that colonoscopy would therefore be coded as a "colonoscopy with intervention", even if the original indication was for "screening".
Section 3: Elevated Complication Risk Groups
Once the population of patients receiving a colonoscopy was selected, each patient was flagged on the basis of their prior diagnoses and prescriptions to divide patients into elevated-risk and average-risk groups.
The elevated-risk group consisted of 2 subcategories, CV risk and pulmonary risk, as defined in Supplementary  Tables 2 and 3 .
To be included in the antithrombotic group, patient must have had each of the following 2 conditions met within the 12 months prior to the index colonoscopy: (1) Patient had a prescription for antiplatelet or anticoagulant medication filled; and (2) Patient had a CPT or ICD-9 diagnosis code associated with a cardiovascular condition (Supplementary Table 2 ). This was done in order to exclude patients prescribed antiplatelet medications for prophylactic and/or acute use to prevent pulmonary embolism.
To be included in the pulmonary group, the patient must have had a CPT or ICD-9 diagnosis code associated with COPD or OSA within the 12 months prior to the index colonoscopy (Supplementary Table 3 ).
Section 4: Post-index Events
Outcomes were the occurrence of non-GI AEs after colonoscopy. Specific codes used to define cardiac, pulmonary, and neurovascular AEs are listed in Supplementary Table 4 . A 30-day look-forward period was used to identify events after the colonoscopy beginning on the day after the colonoscopy procedure (ie, days 1-30 after colonoscopy).
Only events presenting in-hospital or at the emergency department were included; office visits were excluded.
Events were tracked on a per patient basis; thus, only the AE reported for each patient was flagged and tracked. This precludes the possibility of ripple effects (in which one event causes another), minimizing the chance of over-reporting.
Section 5: Multivariate Logistic Regression Analysis Method and Results
A multivariate logistic regression analysis was conducted including the following variables to assess the predictors of non-GI AEs. Two types of patients were selected for Analysis #2, patients receiving a colonoscopy during the index period and a matched set of comparison patients who did not receive a colonoscopy during the index period.
The set of comparison patients was defined in multiple steps, eventually being matched 1:1 to patients in the colonoscopy group on the basis of age group (<18, 18-34, 35-49, 50-59, 60-69, 70-75, >75), gender, and all of the risk factors as described above.
The initial step for identifying the set of comparison patients was selecting every patient in the full database who met the continuous enrollment restriction (March 1, 2010-March 1, 2012) and did not have a colonoscopy during the selection period. In other words, the initial pool of comparison patients consisted of every patient in the continuously enrolled base patient sample who was not one of the index patients identified in Analysis #1 of the study (Supplementary Figure 1) .
The second step in identifying the set of comparison patients was to set the index event date for each comparison patient. An index event date was required to characterize patients on the basis of each of the preindex risk factors and post-index complications. The index event date provided a reference point for the preand post-index (look-back and look-forward) periods. To avoid introducing any potential bias, each patient in the initial set of comparison (non-colonoscopy) patients was assigned a different random index date within the 12-month index period. A random number generator function was used to assign each patient a different random date during the index period.
The third step in identifying the set of comparison patients required evaluation of the same pre-index metrics that were used in Analysis #1. The pre-index attributes were evaluated for every potential comparison patient (all of the non-colonoscopy patients) identified in the first 2 steps. The pre-index attributes were evaluated relative to the randomly assigned index event date for each particular patient.
Once the metrics were collected, an attempt was made to match each colonoscopy patient 1:1 to a single unique non-colonoscopy patient. Patients were matched by using every value from the variables above as well as age group and gender. For example, a single colonoscopy index patient with the attributes Coronary Stents, COPD, Treatment with Oxygen 31-60 days from Index, Age 60-69, and Male would be matched to a single comparison patient with exactly the same set of attributes (and none of the other attributes).
Patients were only matched when all of the patient attributes (age group, gender, and pre-index variables) were the same. Colonoscopy patients without a matching comparison patient were excluded from the analysis.
Section 7: Data Codes for Analysis #2
For Analysis #2, each potential comparison patient was flagged on the basis of their prior diagnoses, procedures, and prescriptions before their randomly assigned index event date. The same set of pre-index variables was created as in Phase 1. In addition, the 1-year pre-index period was used to determine whether the patient had a surgical procedure (CPT 10021-64999, with the exception of CPT 36415: VENPNCTR FNGR/HEEL/EAR STICK ROUTNE). Patients with a prior surgical procedure were excluded from the analysis.
All other codes were identical to those shown above for Analysis #1.
Section 8: IMS LifeLink Health Claims Database References
Examples of publications reporting outcomes in the IMS LifeLink Database are based on a search of PubMed (NLM) on January 13, 2016 for the search terms "IMS LifeLink Health Claims Database" and "LifeLink database". They are listed in reverse chronological order.
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